Diquafosol

DB15919InvestigationalSmall molecule

Diquafosol is a medication indicated to treat dry eyes associated with keratoconjunctival disorders.

Mechanism: Pharmacologically active on P2Y purinoceptor 2, P2Y purinoceptor 1, and P2Y purinoceptor 4
Curator reviewed
Formula / weight: C₁₈H₂₆N₄O₂₃P₄ · 790.306 g/mol (avg)

Resolves to

Compound

Clinical / RWD

Structure

O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O)N1C=CC(=O)NC1=O

Targets

What you can answer from here — as of September 19, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

27Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

4Marketed productsAcross 2 countries and 2 labellers

1ATC codeIncluding every combination product, plus 17 drug categories

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Diquafosol, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.